Novacyt SA (id:10952 ALNOV)
0.576 EUR
Opening hours: 09:00 - 17:30 (Central European Standard Time: 11/22/2024 6:49:26 PM)
Exchange closed, opens in 2 days 14 hours
-0.52 EUR (-0.52%)
-2.37 EUR (-2.37%)
-12.99 EUR (-12.99%)
-25.19 EUR (-25.19%)
-5.73 EUR (-5.73%)
376.82 EUR (376.82%)
-90.05 EUR (-90.05%)
-93.38 EUR (-93.38%)
About Novacyt SA
Market Capitalization 44.14M
Novacyt S.A., together with its subsidiaries, provides in vitro and molecular diagnostic tests for a range of infectious diseases in the United Kingdom, rest of Europe, France, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, and Yourgene Health segments. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Yourgene Health segment delivers molecular diagnostic and screening solutions, across reproductive health and precision medicine. The company was incorporated in 2006 and is based in Eastleigh, the United Kingdom.
| Headquarters (address) |
York House Eastleigh SO53 4DG United Kingdom |
| Phone | 44 2380 748830 |
| Website | https://www.novacyt.com |
| Employees | 240 |
| Sector | Healthcare |
| Industry | Medical Devices |
| Ticker | ALNOV |
| Exchange | European Stock Exchange |
| Currency | EUR |
| 52 week range | 0.493 - 1.59 |
| Market Capitalization | 44.14M |
| P/E trailing | -1.45 |
| P/E forward | 2.32 |
| Price/Sale | 2.38 |
| Price/Book | 0.604 |
| Beta | -1.78 |
| EPS | -0.630 |
| EPS United Kingdom (ID:3, base:637) | 0.429 |